Xponential Fitness Inc (XPOF)
Official siteCONSUMER CYCLICAL • LEISURE • NYSE
Market Cap: $199.81M
Last updated: Nov 17, 2026 at 11:06 AM ET
Xponential Fitness Inc (XPOF) Stock Forecast
Analysts expect Xponential Fitness (XPOF) to earn $0.15 per share in the fiscal year ending Dec 31, 2026, on revenue of $253.78M. Of 8 analysts, 1 rates the stock Buy or Strong Buy, 7 Hold and 0 Sell or Strong Sell, for a consensus of Hold. For the fiscal year ending Dec 31, 2027, the EPS consensus is $0.43.
Analyst Ratings
Scoring Strong Buy as 1 and Strong Sell as 5, the 8 ratings average 2.88, inside the Hold band from 2.5 up to 3.5. Buy and Strong Buy make up 13% of the ratings.
| Rating | Analysts | Share |
|---|---|---|
| Strong Buy | 0 | 0.0% |
| Buy | 1 | 12.5% |
| Hold | 7 | 87.5% |
| Sell | 0 | 0.0% |
| Strong Sell | 0 | 0.0% |
- Consensus
- Hold
- Total analysts
- 8
Price Target
Analyst price targets are part of paid GNG plans. See plans
Annual Estimates
From the first fiscal year below to the second, the EPS consensus rises 186.7% and revenue estimates rise 1.3%.
- Fiscal year ending Dec 31, 2026
- $0.15
- EPS consensus, revenue $253.78M
- Fiscal year ending Dec 31, 2027
- $0.43
- EPS consensus, revenue $257.04M
- Next report
- Feb 24, 2027
- Estimated
EPS range
Revenue range
| Fiscal year ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | $0.15 | $0.06 to $0.19 | 4 | $253.78M | $249.51M to $258.85M | 8 |
| Dec 31, 2027 | $0.43 | $0.20 to $0.69 | 5 | $257.04M | $238.70M to $267.80M | 8 |
Quarterly Estimates
The EPS consensus falls from $0.13 for the quarter ending Dec 31, 2026 to $0.09 for the quarter ending Mar 31, 2027.
EPS range
Revenue range
| Quarter ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | $0.13 | $0.02 to $0.21 | 10 | $65.89M | $59.36M to $70.88M | 10 |
| Mar 31, 2027 | $0.09 | $0.04 to $0.13 | 4 | $62.23M | $56.80M to $66.50M | 6 |
Estimate Revisions
Across the 3 periods below, the last 30 days brought 0 upward and 1 downward EPS revisions.
| Period | Up 30 days | Down 30 days |
|---|---|---|
| Fiscal year ending Dec 31, 2026 | 0 | 0 |
| Fiscal year ending Dec 31, 2027 | 0 | 0 |
| Quarter ending Mar 31, 2027 | 0 | 1 |
EPS Trend
Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has fallen 48.3% from $0.29.
| Period | Now | 7 days ago | 30 days ago | 60 days ago | 90 days ago | Change |
|---|---|---|---|---|---|---|
| Fiscal year ending Dec 31, 2026 | $0.15 | $0.31 | $0.31 | $0.29 | $0.29 | -48.9% |
| Fiscal year ending Dec 31, 2027 | $0.43 | $0.65 | $0.65 | $0.66 | $0.66 | -34.6% |
| Quarter ending Mar 31, 2027 | $0.09 | $0.14 | $0.14 | $0.10 | $0.10 | -5.8% |
Frequently Asked Questions About XPOF
What is the XPOF stock forecast?
Consensus analyst estimates put Xponential Fitness's EPS at $0.15 for the fiscal year ending Dec 31, 2026, on revenue of $253.78M. The consensus rating from 8 analysts is Hold.
How do analysts rate XPOF stock?
Of 8 analysts covering Xponential Fitness, 0 rate it Strong Buy, 1 Buy, 7 Hold, 0 Sell and 0 Strong Sell, for a consensus of Hold.
What EPS do analysts expect from XPOF next year?
For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is $0.15, with estimates from $0.06 to $0.19 from 4 analysts. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is $0.43, with estimates from $0.20 to $0.69 from 5 analysts.
What revenue do analysts expect from Xponential Fitness next year?
For the fiscal year ending Dec 31, 2026, the consensus revenue estimate is $253.78M, with estimates from $249.51M to $258.85M. For the fiscal year ending Dec 31, 2027, the consensus revenue estimate is $257.04M, with estimates from $238.70M to $267.80M.
How many analysts cover XPOF?
8 analysts rate Xponential Fitness stock, and 4 analysts estimate its EPS for the fiscal year ending Dec 31, 2026.
XPOF pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors